The FDA provided a complete response letter to Daiichi Sankyo, alerting them as to the reasons why the new drug application (NDA) for quizartinib as a treatment of adult adults with relapsed/refractory FLT3-ITDā€”positive acute myeloid leukemia (AML) would not be...